Alex Blyth

Alex founded LIfT BioSciences in 2016 after losing his mother to pancreatic cancer and seeing a new way to revolutionise cancer treatment. He is a serial entrepreneur, inventor, economist & biologist with 20 years’ experience in disruptive healthcare. Alex helped to bring to market multiple first-in-class biopharma drugs including T-Vec the first oncolytic vaccine, Erbitux the first cancer drug to use a genetic test to guide use and Abraxane, one of the few drugs licensed for pancreatic cancer in the last decade.